Formulation Development, Optimization And Evaluation Of Solid Self Micro Emulsifying Drug Delivery System (SMEDDS) Of Dexlansoprazole
Abstract
Self-micro emulsifying drug delivery system are prepared in different dosage forms, in which one of the filling in soft and hard hard gelatin capsules resulted in leakage and difficult in manufacturing and loss of material. Dexlansoprazole is a second-generation proton pump inhibitor (PPI) used in the treatment of symptoms of gastroesophageal reflux disease (GERD) and erosive esophagitis (esophageal damage caused by acid in stomach), but because of poor solubility, stability and oral bioavailability. To overcome with the problems the present work was undertaken with an objective to formulate, optimize and evaluate solid SMEDDS (self-micro emulsifying drug delivery system) of Dexlansorazole. The 32 Full factorial designs was applied for the solid SMEDDS formulation of Dexlansoprazole. Prepared capsules were reported and comparisons of in-vitro dissolution of prepared tablet with marketed formulation were performed.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.